Regulus Therapeutics Inc (NASDAQ:RGLS) – Equities researchers at Leerink Swann raised their Q1 2018 EPS estimates for shares of Regulus Therapeutics in a note issued to investors on Thursday. Leerink Swann analyst J. Schwartz now forecasts that the biopharmaceutical company will earn ($0.20) per share for the quarter, up from their prior forecast of ($0.23). Leerink Swann currently has a “Outperform” rating and a $2.00 target price on the stock. Leerink Swann also issued estimates for Regulus Therapeutics’ Q2 2018 earnings at ($0.20) EPS, Q3 2018 earnings at ($0.20) EPS, Q4 2018 earnings at ($0.21) EPS, FY2018 earnings at ($0.80) EPS, FY2019 earnings at ($0.62) EPS, FY2020 earnings at ($0.51) EPS, FY2021 earnings at ($0.54) EPS and FY2022 earnings at ($0.52) EPS.
Several other equities analysts also recently issued reports on RGLS. Zacks Investment Research downgraded shares of Regulus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, January 18th. Chardan Capital reiterated a “neutral” rating on shares of Regulus Therapeutics in a research report on Tuesday, January 16th. BMO Capital Markets set a $1.00 price objective on shares of Regulus Therapeutics and gave the stock a “hold” rating in a research report on Thursday, March 8th. Wedbush reiterated an “outperform” rating and set a $4.00 price objective on shares of Regulus Therapeutics in a research report on Monday, December 11th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Regulus Therapeutics in a research report on Tuesday, November 14th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $2.20.
Regulus Therapeutics (NASDAQ:RGLS) last released its quarterly earnings results on Wednesday, March 7th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.17) by $0.03. The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.02 million. Regulus Therapeutics had a negative net margin of 99,868.07% and a negative return on equity of 201.84%.
Several institutional investors and hedge funds have recently bought and sold shares of RGLS. BVF Inc. IL increased its position in shares of Regulus Therapeutics by 7.9% during the fourth quarter. BVF Inc. IL now owns 13,974,249 shares of the biopharmaceutical company’s stock worth $14,533,000 after buying an additional 1,025,020 shares during the period. Ascend Capital LLC acquired a new stake in shares of Regulus Therapeutics during the fourth quarter worth $1,053,000. Candriam Luxembourg S.C.A. acquired a new stake in shares of Regulus Therapeutics during the third quarter worth $750,000. South Dakota Investment Council increased its position in shares of Regulus Therapeutics by 37.1% during the third quarter. South Dakota Investment Council now owns 1,820,027 shares of the biopharmaceutical company’s stock worth $2,275,000 after buying an additional 492,969 shares during the period. Finally, Victory Capital Management Inc. acquired a new stake in shares of Regulus Therapeutics during the third quarter worth $347,000. Institutional investors own 53.72% of the company’s stock.
About Regulus Therapeutics
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.